$2.5M/4-Year DoD CDMPR Contract to BioSensics

We are excited to share that BioSensics has been awarded a ~$2.5M/4-year grant through the DoD Congressionally Directed Medical Research Programs (CDMRP). This award will facilitate the advancement of our efforts to develop and validate remote measurement technologies and digital biomarkers for frontotemporal lobar degeneration (FTLD) syndromes. These syndromes encompass a range of neurodegenerative disorders impacting both movement and cognitive function, and they are closely associated with Alzheimer’s disease.

In 2022, BioSensics was awarded a $2.5M/4-year Small Business Innovation Research (SBIR) grant by the National Institute on Aging to develop a multi-modal remote monitoring solution for FTLD syndromes and validate it in progressive supranuclear palsy. Subsequently, in January 2024, BioSensics received the AFTD-ALS Association Digital Assessment Tools for FTD and ALS Award. This award aims to support a pilot study using the developed solution in frontotemporal dementia (FTD) and corticobasal syndrome (CBS).

The DoD CDMRP award will expand our efforts in FTD and CBS by recruiting a diverse patient cohort at Massachusetts General Hospital (led by Anne-Marie Wills, M.D., and Brad Dickerson, M.D.), and Johns Hopkins University (led by Alex Pantelyat, M.D., and Chiadi Onyike, M.D.).

This work was supported by The Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, in the amount of $2,463,953, through the Peer Reviewed Medical Research Program under Award Number HT9425-24-1-0421. Opinions, interpretations, conclusions, and recommendations contained herein are those of the author(s) and are not necessarily endorsed by the Department of Defense.